Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexicon Pharmaceuticals (LXRX) EBITDA Margin (2024 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed EBITDA Margin for 4 consecutive years, with 12.94% as the latest value for Q2 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 12.94% in Q2 2025 year-over-year; TTM through Sep 2025 was 257.06%, a 987357.0% increase, with the full-year FY2011 number at 6170.63%, down 388674.0% from a year prior.
  • EBITDA Margin was 12.94% for Q2 2025 at Lexicon Pharmaceuticals, up from 3672.51% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 12.94% in Q2 2025 to a low of 3672.51% in Q3 2024.